COMMUNIQUÉS West-GlobeNewswire

INmune Bio Announces Submission of Phase 2 MINDFuL Trial Results in Alzheimer’s Disease to npj Dementia, a Nature Portfolio Journal
29/09/2025
Boca Raton, FL, Sept. 29, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces the submission of a manuscript detailing the results of its Phase [...]
MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum
29/09/2025
CARMEL, Ind., Sept. 29, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the [...]
electroCore Announces Reimbursement Approval for gammaCore™ by RIZIV/INAMI in Belgium
29/09/2025
ROCKAWAY, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that gammaCore™ Sapphire (nVNS) has been included in a [...]
Humacyte Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered Esophagus
29/09/2025
– Patent covers esophagus produced using Humacyte’s proprietary bioengineered regenerative tissue platform, designed for implant in patients with damaged esophagus – – Patent provides coverage into 2041 for the [...]
Calidi Biotherapeutics to Present at the second annual Oncology Venture, Innovation, and Partnering Summit in Boston
29/09/2025
SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of targeted therapies with [...]
Apyx Medical to Host Virtual Key Opinion Leader Event to Discuss the Commercial Launch of The AYON Body Contouring System™ on October 14, 2025
29/09/2025
CLEARWATER, Fla., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and [...]
Provectus Biopharmaceuticals Initiates Preclinical Study of Oral PV-10 in Bladder Cancer
29/09/2025
KNOXVILLE, Tenn., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced the start of a preclinical study of its lead investigational drug PV- [...]
Reflect Scientific Secures Over $1 Million in Follow-On Orders for B-90 Blast Freezer
29/09/2025
OREM, Utah, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (Symbol: RSCF), a provider of advanced cryogenic cooling solutions, today announced it has received follow-on orders totaling more than $1 million [...]
MindRank Announces Positive 12-week Once-Daily (QD) Results for AI-Designed Oral GLP-1 Agonist MDR-001 in Adults with Obesity
29/09/2025
HANGZHOU, China and LONDON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- MindRank AI Ltd., a clinical-stage artificial intelligence (AI)-empowered drug discovery company, today announced the positive topline results of its oral [...]
Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026
29/09/2025
Phase 2 randomized, double-blind, placebo-controlled trial planned to evaluate TNX-2900 in children and adolescents (ages 8 to 17.5 years) with Prader-Willi Syndrome under a cleared IND TNX-2900 granted Orphan Drug and [...]
AdvanCell to Highlight the Potential of Pb-212-based Targeted Alpha Therapies for Cancer at EANM’25
29/09/2025
Sydney, Australia – September 29, 2025 – AdvanCell, a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer, today announced that it will present six abstracts at the 2025 Annual [...]
Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s Ataxia
29/09/2025
In 4 completed studies and the ongoing OL study, 65 participants received at least 1 dose of nomlabofusp, including 39 in the OL study, with 14 on treatment for at least 6 months and 8 for over 1 year in the OL study [...]
Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren’s Disease Clinical Study at ACR Convergence 2025
29/09/2025
BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data from the Phase 3 study in [...]
Applied Therapeutics Provides Update Following Meeting with FDA
29/09/2025
NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the Company), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare diseases, today [...]
Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN
29/09/2025
New preclinical data demonstrate deeper IgA reduction and a longer half-life compared to first-generation anti-APRIL monoclonal antibody CLYM116 Phase 1 trial initiation expected in Q4 2025, with initial biomarker and [...]
MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer
29/09/2025
WESTLAKE VILLAGE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for [...]
RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy
29/09/2025
RAPT on track to initiate trial this year SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on [...]
Inventiva reports its unaudited 2025 first-half financial results and provides a corporate update
29/09/2025
Cash and cash equivalents at €146.7 million including €24.6 million in short-term deposits 1 as of June 30, 2025 Receipt of the gross proceeds of €115.6 million from the second tranche of the structured financing of up [...]
Inventiva publie ses résultats financiers non audités du premier semestre 2025 et fait le point sur ses activités
29/09/2025
Trésorerie et équivalents de trésorerie à 122,1 millions d’euros et dépôts à court terme 1 à 24,6 millions d’euros au 30 juin 2025 Produit brut de 115,6 millions d’euros reçu au titre de la deuxième tranche du [...]

Pages